Anticorps Polyclonal de lapin anti-ECD

• Phare
• Validé par KD/KO

ECD Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IHC, IF/ICC, IP, RIP, ELISA

Conjugaison

Non conjugué

Publications(5)

N° de cat : 10192-1-AP

Synonymes

Protein ecdysoneless homolog, Human suppressor of GCR two, hSGT1

---

Galerie de données de validation

• 

  WB analysis of HeLa using 10192-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10192-1-AP (ECD antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 10192-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10192-1-AP (ECD antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 10192-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10192-1-AP (ECD antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 10192-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10192-1-AP (ECD antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HeLa using 10192-1-AP

  IP result of anti-ECD (IP:10192-1-AP, 4ug; Detection:10192-1-AP 1:300) with HeLa cells lysate 2480ug.

• 

  IHC staining of human ovary cancer using 10192-1-AP

  Immunohistochemical analysis of paraffin-embedded human ovary cancer tissue slide using 10192-1-AP (ECD antibody) at dilution of 1:200 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of HeLa using 10192-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HeLa cells using ECD antibody (10192-1-AP) at dilution of 1:200 and CoraLite®594-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-4).

---

Applications testées

• Résultats positifs en WB: cellules HeLa
• Résultats positifs en IP: cellules HeLa
• Résultats positifs en IHC: human ovary cancer tissue, ; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:1000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:50-1:500
• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 3 publications below
• IF: See 1 publications below
• RIP: See 3 publications below

Informations sur le produit

10192-1-AP cible ECD dans les applications de WB, IHC, IF/ICC, IP, RIP, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: ECD Protéine recombinante Ag0245
• Nom complet: ecdysoneless homolog (Drosophila)
• Masse moléculaire calculée: 73 kDa
• Poids moléculaire observé: 73 kDa
• Numéro d’acquisition GenBank: BC000721
• Symbole du gène: ECD
• Identification du gène (NCBI): 11319
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

The human suppressor of GCR two (hSGT1) was isolated by its ability to complement the growth defect of the gcr2 mutant of Saccharomyces cerevisiae. Further work confirmed that the rescue of growth was associated with recovery of glycolytic enzyme activities of gcr2, and that hSGT1 did not complement the growth defect of a gcr1 mutant. A hybrid protein comprising hSgt1p and the DNA-binding domain of Gal4p (GBD) activated a GAL1-lacZ reporter gene fusion, suggesting that the cloned gene may be a transcriptional activator. Two-hybrid experiments in yeast also indicate that hSgt1p interacts with Gcr1p. Northern analysis showed that hSGT1 is highly expressed in muscle and heart.

Publications

Species	Application	Title
human	WB	Oncotarget; Amplification of ACK1 promotes gastric tumorigenesis via ECDdependent p53 ubiquitination degradation.; Authors - Song-Hui Xu ; KD Validated
human	RIP	bioRxiv; ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis; Authors - Mohsin Raza
human	WB,IF	J Adv Res; Transcriptional regulation of Rankl by Txnip-Ecd in aging and diabetic related osteoporosis; Authors - Xiankun Cao
human	RIP	bioRxiv; ECD functions as a novel RNA-binding protein to regulate mRNA splicing; Authors - Mohsin Raza
human	WB,RIP	bioRxiv; ECD co-operates with ERBB2 to promote tumorigenesis through upregulation of unfolded protein response and glycolysis; Authors - Benjamin B Kennedy

{{ptg:RelatedPrimaryAntibodies}}